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 Dihydroartemisinin-piperaquine: if it works for control, can 
we use it for elimination?
Historically, antimalarial drugs have been used at 
a popu lation level in malaria-endemic areas with 
the objective of decreasing the burden, impact, and 
transmissibility of malaria.1 Continuous chemo pro-
phylaxis, once experimented but never seriously con-
sidered a feasible wide-scale implementable strategy, 
has been superseded by the concept of intermittent 
treatment targeting diﬀ erent population groups, 
presenting many advantages, including non-inter-
ference with the acquisition of natural immunity against 
malaria. A fundamental premise for the use of any drug 
as part of population wide distribution eﬀ orts, besides 
its eﬃ  cacy, is that the drug is suﬃ  ciently safe so as to 
not to risk endangering the healthy individuals that will 
be exposed to it. The artemisinin-derived combination 
dihydroartemisinin-piperaquine (DP), registered under 
the European Medicines Agency in 2011,2 would appear 
as an ideal candidate for the treatment of malaria, 
not only because of its high-demonstrated eﬃ  cacy, 
but on account of its excellent tolerability and good 
safety proﬁ le, well reported in the literature.3–5 From a 
preventive point of view, the long half-life of the partner 
drug piperaquine conveys protection of 22 days for adult 
patients and around 20 days for paediatric patients,2 
indicating a better post-treatment prophylactic eﬀ ect 
than other combination therapies.3,6,7 In the Lancet 
Infectious Diseases, Julie Gutman and colleagues analyse 
the safety, tolerability, and eﬃ  cacy of repeated doses of 
DP, for the treatment and prevention of malaria, with 
a particular focus on its use as intermittent preventive 
treatment (IPT).8 Their meta-analysis, looking at over 
4000 patients exposed to repeated courses of DP, 
substantiates the high eﬃ  cacy of this drug in terms of 
controlling malaria and all-cause hospital admission, 
and the good tolerability of repeated treatment 
schemes, with no evidence of arrhythmias secondary 
to the potential QT prolongation eﬀ ect of cumulative 
doses of piperaquine after repeated doses. Although 
numbers are clearly insuﬃ  cient to rule out this rare, 
life-threatening complication, and the small number 
of carefully ECG monitored patients calls for caution 
and further cardio safety studies, this analysis adds 
up to the growing body of evidence supporting the 
potential of this drug for IPT strategies. as an alternative 
to the currently recommended drugs. In areas where 
transmission remains high, it may be prudent to restrict 
ACTs for the treatment of cases, and not overexpose this 
drug family for prophylactic purposes.9 
The authors are, however, shy to extend their recom-
mendations for the use of DP for elimination purposes. 
Indeed, many of the considerations that they ponder 
for the use of DP as IPT in restricted population groups, 
including repeated dosing, apply to its wider use in 
mass drug administration (MDA) campaigns that target 
the interruption of transmission. It is precisely DP’s 
longer-lasting post-treatment prophylactic eﬀ ect that 
is appealing as an elimination drug, being the basis for 
massive use in Zambia10 and Mozambique11 in ambitious 
malaria elimination demonstration projects. In 
elimination settings, careful pharmacovigilance should 
be coupled to the assessment of the eﬀ ectiveness of 
drug deployment, and inform on the occurrence of 
rarer safety events, so as to help build a more deﬁ nitive 
case for the adequacy of the chosen drug for MDA. If 
transmission is successfully interrupted, legitimate 
concerns on the risks of fuelling drug resistance should 
become less pressing.
Pregnant women and very young children are 
often neglected in the assessment of the eﬃ  cacy and 
safety of new drugs, or new uses of already existing 
drugs. For DP, this is not the case, and a robust 
portfolio of data has been compiled in recent years, 
both regarding the treatment and prevention of 
malaria during pregnancy6,12 and infancy13 including 
the recent development of a dispersible paediatric 
formulation (NCT01992900). The safety and 
pharma cological interactions of IPTp-SP need to be 
assessed in HIV-positive pregnant women already 
receiving antiretrovirals, understanding that in this 
particularly vulnerable group, the use of sulphadoxine-
pyrimethamine is incompatible with cotrimoxazole 
prophylaxis. 
Current WHO recommendations for the use of ACTS in 
pregnancy approach acceptance of ACT use throughout 
the entire pregnancy, because the risk-beneﬁ t ratio 
still favours the quick elimination of malaria infections 
Lancet Infect Dis 2016
Published Online
November 16, 2016
http://dx.doi.org/10.1016/
S1473-3099(16)30459-5
See Online/Articles
http://dx.doi.org/10.1016/
S1473-3099(16)30378-4
To
n 
Ko
en
e/
DP
A/
PA
 Im
ag
es
 
Comment
2 www.thelancet.com/infection   Published online November 16, 2016   http://dx.doi.org/10.1016/S1473-3099(16)30459-5
in vulnerable pregnant populations.9 In MDA eﬀ orts, 
however, use of ACTs in the ﬁ rst term of pregnancy should 
not be recommended, as the risks of exposing healthy 
uninfected pregnant women outweigh the potential 
community beneﬁ ts of interrupting transmission. For 
this reason, adequate pregnancy detection strategies are 
mandatory in malaria MDA eﬀ orts using ACTs. 
Debate is necessary for more proactive use of drugs 
to achieve the immensely ambitious goal of malaria 
eradication, but for the time being, DP seems to be a 
good candidate, both for IPT and elimination purposes.
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